RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, May 2026: A Home Neurostimulator for PTSD, Four De Novo Grants and Five Original PMAs

日本語版

One of FDA's four De Novo grants in May 2026 went to Modius Spero (DEN250013), a home-use device worn on the head that applies electrical stimulation to treat symptoms associated with post-traumatic stress disorder. The grant created a new classification for transcranial nerve stimulation in post-traumatic stress disorder (PTSD).

The month's De Novo grants also include the DeepView AI System (DEN250028) for burn assessment, which we covered in a separate spotlight. Four of the five original PMAs were in vitro diagnostics.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 277 510(k)s in May 2026, granted 4 De Novo requests and approved 5 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

May 2026 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayMay 2026April 2026May 2025
510(k)277314298
De Novo434
PMA (original)513
PMA supplement208209176

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 37 fewer than in April and below May 2025 (298). Original PMAs rose from 1 in April to 5.

The busiest product codes

May's 510(k)s spread across 181 product codes. IYN (system, imaging, pulsed doppler, ultrasonic) led with 11, followed by QIH (automated radiological image processing software) with 10 and GEX (powered laser surgical instrument) with 8. LLZ (system, image processing, radiological), MAX (intervertebral fusion device with bone graft, lumbar) and OLO (orthopedic stereotaxic instrument) had 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: four classifications

May's four De Novo grants, all Class II, with the classification names and regulation numbers from each Classification Order:

  • Prolystica Pass Thru Disinfectant Wipes (DEN240075, Steris): Interim reprocessing cleaning and intermediate-level disinfection wipe (21 CFR 880.6891)
  • Modius Spero (DEN250013, Neurovalens Limited): Transcranial nerve stimulation device for the treatment of post-traumatic stress disorder associated symptoms (21 CFR 882.5807)
  • DeepView AI® System (DEN250028, Spectral MD, Inc.): Software-aided adjunctive diagnostic device for use by healthcare providers in skin wound assessment (21 CFR 878.1840)
  • PCWP Analysis Software (DEN250057, Cardiosense, Inc.): Software device system for estimation of cardiac pressures (21 CFR 870.1150)

"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.

Prolystica wipes clean and intermediate-level disinfect non-submersible or heat-sensitive devices before terminal sterilization or high-level disinfection. The classification makes clear that the wipe is not a terminal reprocessing step.

Original PMAs: five approvals, four of them diagnostics

  • LIAISON Biotrin Parvovirus B19 IgM Plus (P250039, DiaSorin, Inc.): a chemiluminescent immunoassay for IgM antibodies to parvovirus B19 (product code MYM)
  • Atellica IM free PSA II (P250026, Siemens Healthcare Diagnostics, Inc.): measures free prostate-specific antigen (PSA) so that percent free PSA can help distinguish prostate cancer from benign disease in men 50 and older with total PSA of 4 to 10 ng/mL (MTG)
  • Signatera™ CDx (P260004, Natera, Inc.): a tumor-informed blood test that determines molecular residual disease (MRD) status from circulating tumor DNA (ctDNA), used as a companion diagnostic (PQP)
  • Belotero Volume (+) Lidocaine (P250020, Merz North America, Inc.): a dermal filler for mid-face volume deficit (LMH)
  • Guardant360® Liquid CDx (P250027, Guardant Health, Inc.): a plasma cell-free DNA sequencing panel that detects tumor mutations, used as a companion diagnostic (PQP)

May also brought 208 PMA supplements, which cover changes to already approved PMA devices among other things.

Three devices worth a closer read

1. Modius Spero (DEN250013, De Novo). A prescription device for home use by adults 22 and older with PTSD symptoms, under the direction of a healthcare professional and as part of a comprehensive treatment plan. Among its six special controls, the labeling must say that the device is not a stand-alone therapy and does not change usual care, that a physician should monitor for side effects and worsening symptoms, and how to manage side effects such as dizziness and headache.

2. PCWP Analysis Software (DEN250057, De Novo). For patients with heart failure with reduced ejection fraction and New York Heart Association (NYHA) class II to IV symptoms, the software noninvasively estimates pulmonary capillary wedge pressure and identifies whether it is above or below 18 mmHg. Its fifth special control is a postmarket performance management plan: assess real-world performance and generalizability regularly, detect and explain changes, assess their impact, and tell users how the device currently performs. The classification name, estimation of cardiac pressures, is broad enough to cover left ventricular end-diastolic pressure and pulmonary artery pressure as well.

3. Signatera™ CDx (P260004, PMA). The test sequences the patient's tumor and matched normal blood to choose patient-specific variants, then tracks them in plasma to call ctDNA molecular residual disease status. The approved indication is to identify patients with muscle-invasive bladder cancer who are MRD-positive and may benefit from atezolizumab. Patients are selected by MRD status rather than by a specific mutation, and the approval comes with five post-approval study conditions.

Compare the three devices

Open DEN250013, DEN250057 and P260004, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles